Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
77 hedge funds and large institutions have $33M invested in Seelos Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 25 reducing their positions, and 15 closing their positions.
539% more call options, than puts
Call options by funds: $786K | Put options by funds: $123K
6% less funds holding
Funds holding: 82 → 77 (-5)
12% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 25
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
51% less capital invested
Capital invested by funds: $67.8M → $33M (-$34.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GJL
Gendell Jeffrey L
|
+$2.78M |
| 2 |
Renaissance Technologies
New York
|
+$1.92M |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$1.42M |
| 4 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$581K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$568K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$3.48M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.47M |
| 3 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
-$1.99M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$1.39M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$1.28M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$1K | – | – |
|
|
CA
102
CoreCap Advisors
Southfield,
Michigan
| – | -$1K | – | – |
|
|
RA
103
Resolute Advisors
San Francisco,
California
| – | -$2K | – | – |
|
|
TC
104
TAP Consulting
Kirkwood,
Missouri
| – | -$2K | – | – |
|
SEEL Hedge Fund Activity: Q1 2022 in Review
77 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q1 2022, worth a combined $33M — down 51% from $67.8M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of SEEL and 10 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 22 added.
The largest buyer was Gendell Jeffrey L, adding an estimated $2.78M. The largest seller was Mangrove Partners, exiting entirely with an estimated $3.48M sold.
- 77 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q1 2022, down from 82 in Q4 2021.
- Funds reported $33M of Seelos Therapeutics, Inc. Common Stock stock for Q1 2022, down 51% quarter-over-quarter.
- 10 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q1 2022 and 15 closed out, a net change of -5 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q1 2022 was Gendell Jeffrey L, an estimated $2.78M added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q1 2022 was Mangrove Partners, an estimated $3.48M sold.
Based on aggregated 13F filings for Q1 2022.